Harmeet Sidhu
Keine laufenden Positionen mehr
Karriereverlauf von Harmeet Sidhu
Ehemalige bekannte Positionen von Harmeet Sidhu
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ixion Biotechnology, Inc.
 Ixion Biotechnology, Inc. BiotechnologyHealth Technology Ixion Biotechnology, Inc. develops somatic cellular therapies to treat diabetes. The company was founded by Weaver H. Gaines and David C. Peck on April 4, 1994 and is headquartered in Alachua, FL. | Geschäftsführer | 01.12.2002 | - |
| Präsident | 01.12.2002 | - |
Ausbildung von Harmeet Sidhu
| Post Graduate Institute of Medical Education & Research | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 2 |
| Schweden | 2 |
| Indien | 2 |
Operativ
| Chief Operating Officer | 1 |
| President | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Ixion Biotechnology, Inc.
Ixion Biotechnology, Inc. BiotechnologyHealth Technology Ixion Biotechnology, Inc. develops somatic cellular therapies to treat diabetes. The company was founded by Weaver H. Gaines and David C. Peck on April 4, 1994 and is headquartered in Alachua, FL. | Health Technology |
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |
- Börse
- Insiders
- Harmeet Sidhu
- Erfahrung
